Preview study has demonstrated that GSK-J4-mediated inhibition of JMJD3 can sensitize germinal center B-cell diffuse large B-cell lymphoma cells to chemotherapy agents [30]. This evidence concerns the gene KDM6B and diffuse large B-cell lymphoma.